{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:21:49Z","timestamp":1793413309956,"version":"4.5.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":63,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the Sixth Round of Quanzhou City's High-Level Talent Team Recruitment Project","award":["2023CT007"],"award-info":[{"award-number":["2023CT007"]}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["W2441013"],"award-info":[{"award-number":["W2441013"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of Fujian Province","award":["2021J01016"],"award-info":[{"award-number":["2021J01016"]}]},{"name":"the Second Affiliated Hospital of Fujian Medical University Ph.D. Seedling Project","award":["BS202104"],"award-info":[{"award-number":["BS202104"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biosci"],"DOI":"10.1186\/s13578-026-01592-1","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:14:53Z","timestamp":1780042493000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Monoclonal antibody passive experimental autoimmune myasthenia gravis: current progress and future directions"],"prefix":"10.1186","volume":"16","author":[{"given":"Liting","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianghao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siying","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"1592_CR1","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41582-023-00916-w","volume":"20","author":"R Iorio","year":"2024","unstructured":"Iorio R. Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat Rev Neurol. 2024;20:84\u201398.","journal-title":"Nat Rev Neurol"},{"key":"1592_CR2","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","volume":"5","author":"NE Gilhus","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J. Myasthenia gravis. Nat Rev Dis Primers. 2019;5:30.","journal-title":"Nat Rev Dis Primers"},{"key":"1592_CR3","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1126\/science.180.4088.871","volume":"180","author":"J Patrick","year":"1973","unstructured":"Patrick J, Lindstrom J. Autoimmune response to acetylcholine receptor. Science. 1973;180:871\u20132.","journal-title":"Science"},{"key":"1592_CR4","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1126\/science.1179220","volume":"190","author":"KV Toyka","year":"1975","unstructured":"Toyka KV, Brachman DB, Pestronk A, Kao I. Myasthenia gravis: passive transfer from man to mouse. Science. 1975;190:397\u20139.","journal-title":"Science"},{"key":"1592_CR5","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.jneuroim.2006.03.016","volume":"175","author":"S Jha","year":"2006","unstructured":"Jha S, Xu K, Maruta T, Oshima M, Mosier DR, Atassi MZ, et al. Myasthenia gravis induced in mice by immunization with the recombinant extracellular domain of rat muscle-specific kinase (musk). J Neuroimmunol. 2006;175:107\u201317.","journal-title":"J Neuroimmunol"},{"key":"1592_CR6","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1172\/JCI21545","volume":"116","author":"K Shigemoto","year":"2006","unstructured":"Shigemoto K, Kubo S, Maruyama N, Hato N, Yamada H, Jie C, et al. Induction of myasthenia by immunization against muscle-specific kinase. J Clin Invest. 2006;116:1016\u201324.","journal-title":"J Clin Invest"},{"key":"1592_CR7","doi-asserted-by":"publisher","first-page":"e975","DOI":"10.1212\/WNL.0000000000012463","volume":"97","author":"Z Yu","year":"2021","unstructured":"Yu Z, Zhang M, Jing H, Chen P, Cao R, Pan J, et al. Characterization of lrp4\/agrin antibodies from a patient with myasthenia gravis. Neurology. 2021;97:e975\u201387.","journal-title":"Neurology"},{"key":"1592_CR8","doi-asserted-by":"publisher","first-page":"5190","DOI":"10.1172\/JCI66039","volume":"123","author":"C Shen","year":"2013","unstructured":"Shen C, Lu Y, Zhang B, Figueiredo D, Bean J, Jung J, et al. Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest. 2013;123:5190\u2013202.","journal-title":"J Clin Invest"},{"key":"1592_CR9","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.neuroscience.2018.01.015","volume":"373","author":"M Yan","year":"2018","unstructured":"Yan M, Liu Z, Fei E, Chen W, Lai X, Luo B, et al. Induction of anti-agrin antibodies causes myasthenia gravis in mice. Neuroscience. 2018;373:113\u201321.","journal-title":"Neuroscience"},{"key":"1592_CR10","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/IJGM.S88552","volume":"9","author":"R Mantegazza","year":"2016","unstructured":"Mantegazza R, Cordiglieri C, Consonni A, Baggi F. Animal models of myasthenia gravis: utility and limitations. Int J Gen Med. 2016;9:53\u201364.","journal-title":"Int J Gen Med"},{"key":"1592_CR11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/0165-5728(87)90067-1","volume":"13","author":"E Buschman","year":"1987","unstructured":"Buschman E, van Oers N, Katz M, Murgita RA. Experimental myasthenia gravis induced in mice by passive transfer of human myasthenic immunoglobulin. Evidence for an ameliorating effect by alpha-fetoprotein. J Neuroimmunol. 1987;13:315\u201330.","journal-title":"J Neuroimmunol"},{"key":"1592_CR12","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/ana.21371","volume":"63","author":"RN Cole","year":"2008","unstructured":"Cole RN, Reddel SW, Gervasio OL, Phillips WD. Anti-musk patient antibodies disrupt the mouse neuromuscular junction. Ann Neurol. 2008;63:782\u20139.","journal-title":"Ann Neurol"},{"key":"1592_CR13","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/285238a0","volume":"285","author":"VA Lennon","year":"1980","unstructured":"Lennon VA, Lambert EH. Myasthenia gravis induced by monoclonal antibodies to acetylcholine receptors. Nature. 1980;285:238\u201340.","journal-title":"Nature"},{"key":"1592_CR14","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1073\/pnas.77.2.755","volume":"77","author":"SJ Tzartos","year":"1980","unstructured":"Tzartos SJ, Lindstrom JM. Monoclonal antibodies used to probe acetylcholine receptor structure: localization of the main immunogenic region and detection of similarities between subunits. Proc Natl Acad Sci U S A. 1980;77:755\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1592_CR15","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/0014-5793(83)80688-7","volume":"158","author":"S Tzartos","year":"1983","unstructured":"Tzartos S, Langeberg L, Hochschwender S, Lindstrom J. Demonstration of a main immunogenic region on acetylcholine receptors from human muscle using monoclonal antibodies to human receptor. FEBS Lett. 1983;158:116\u20138.","journal-title":"FEBS Lett"},{"key":"1592_CR16","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1073\/pnas.79.1.188","volume":"79","author":"SJ Tzartos","year":"1982","unstructured":"Tzartos SJ, Seybold ME, Lindstrom JM. Specificities of antibodies to acetylcholine receptors in sera from myasthenia gravis patients measured by monoclonal antibodies. Proc Natl Acad Sci U S A. 1982;79:188\u201392.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1592_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1600-065X.1998.tb01190.x","volume":"163","author":"SJ Tzartos","year":"1998","unstructured":"Tzartos SJ, Barkas T, Cung MT, Mamalaki A, Marraud M, Orlewski P, et al. Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor. Immunol Rev. 1998;163:89\u2013120.","journal-title":"Immunol Rev"},{"key":"1592_CR18","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1021\/bi00511a017","volume":"20","author":"B Conti-Tronconi","year":"1981","unstructured":"Conti-Tronconi B, Tzartos S, Lindstrom J. Monoclonal antibodies as probes of acetylcholine receptor structure. 2. Binding to native receptor. Biochemistry. 1981;20:2181\u201391.","journal-title":"Biochemistry"},{"key":"1592_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.746068","volume":"13","author":"J Song","year":"2022","unstructured":"Song J, Zhao R, Yan C, Luo S, Xi J, Ding P, et al. A targeted complement inhibitor crig\/fh protects against experimental autoimmune myasthenia gravis in rats via immune modulation. Front Immunol. 2022;13:746068.","journal-title":"Front Immunol"},{"key":"1592_CR20","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/eji.1830111212","volume":"11","author":"MS Neuberger","year":"1981","unstructured":"Neuberger MS, Rajewsky K. Activation of mouse complement by monoclonal mouse antibodies. Eur J Immunol. 1981;11:1012\u20136.","journal-title":"Eur J Immunol"},{"key":"1592_CR21","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/imr.12350","volume":"268","author":"P Bruhns","year":"2015","unstructured":"Bruhns P, Jonsson F. Mouse and human fcr effector functions. Immunol Rev. 2015;268:25\u201351.","journal-title":"Immunol Rev"},{"key":"1592_CR22","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/0165-5728(87)90092-0","volume":"15","author":"S Tzartos","year":"1987","unstructured":"Tzartos S, Hochschwender S, Vasquez P, Lindstrom J. Passive transfer of experimental autoimmune myasthenia gravis by monoclonal antibodies to the main immunogenic region of the acetylcholine receptor. J Neuroimmunol. 1987;15:185\u201394.","journal-title":"J Neuroimmunol"},{"key":"1592_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1526317","volume":"16","author":"I Michailidou","year":"2025","unstructured":"Michailidou I, Patsiarika A, Kesidou E, Boziki MK, Parisis D, Bakirtzis C, et al. The role of complement in the immunopathogenesis of acetylcholine receptor antibody-positive generalized myasthenia gravis: Bystander or key player? Front Immunol. 2025;16:1526317.","journal-title":"Front Immunol"},{"key":"1592_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/nyas.13522","volume":"1412","author":"JF Howard Jr.","year":"2018","unstructured":"Howard JF Jr. Myasthenia gravis: The role of complement at the neuromuscular junction. Ann N Y Acad Sci. 2018;1412:113\u201328.","journal-title":"Ann N Y Acad Sci"},{"key":"1592_CR25","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1126\/science.1144603","volume":"317","author":"M van der Neut Kolfschoten","year":"2007","unstructured":"van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martinez-Martinez P, Vermeulen E, et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science. 2007;317:1554\u20137.","journal-title":"Science"},{"key":"1592_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1046\/j.0019-2805.2001.01341.x","volume":"105","author":"RC Aalberse","year":"2002","unstructured":"Aalberse RC, Schuurman J. Igg4 breaking the rules. Immunology. 2002;105:9\u201319.","journal-title":"Immunology"},{"key":"1592_CR27","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1016\/j.cell.2025.03.004","volume":"188","author":"H Li","year":"2025","unstructured":"Li H, Pham MC, Teng J, O\u2019Connor KC, Noviello CM, Hibbs RE. Autoimmune mechanisms elucidated through muscle acetylcholine receptor structures. Cell. 2025;188:2390-2406 e2320.","journal-title":"Cell"},{"key":"1592_CR28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2408324121","volume":"121","author":"J Oury","year":"2024","unstructured":"Oury J, Gamallo-Lana B, Santana L, Steyaert C, Vergoossen DLE, Mar AC, et al. Agonist antibody to Musk protects mice from Musk myasthenia gravis. Proc Natl Acad Sci U S A. 2024;121:e2408324121.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1592_CR29","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000547","volume":"6","author":"MG Huijbers","year":"2019","unstructured":"Huijbers MG, Vergoossen DL, Fillie-Grijpma YE, van Es IE, Koning MT, Slot LM, et al. Musk myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity. Neurol Neuroimmunol Neuroinflamm. 2019;6:e547.","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1592_CR30","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1002\/eji.1830220939","volume":"22","author":"H Loutrari","year":"1992","unstructured":"Loutrari H, Kokla A, Tzartos SJ. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor. Eur J Immunol. 1992;22:2449\u201352.","journal-title":"Eur J Immunol"},{"key":"1592_CR31","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/256495a0","volume":"256","author":"G Kohler","year":"1975","unstructured":"Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495\u20137.","journal-title":"Nature"},{"key":"1592_CR32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.crimmu.2021.03.002","volume":"2","author":"JZ Moraes","year":"2021","unstructured":"Moraes JZ, Hamaguchi B, Braggion C, Speciale ER, Cesar FBV, Soares G, et al. Hybridoma technology: Is it still useful? Curr Res Immunol. 2021;2:32\u201340.","journal-title":"Curr Res Immunol"},{"key":"1592_CR33","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.jim.2009.08.009","volume":"350","author":"T Tiller","year":"2009","unstructured":"Tiller T, Busse CE, Wardemann H. Cloning and expression of murine ig genes from single b cells. J Immunol Methods. 2009;350:183\u201393.","journal-title":"J Immunol Methods"},{"key":"1592_CR34","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1084\/jem.20090299","volume":"206","author":"B Pollinger","year":"2009","unstructured":"Pollinger B, Krishnamoorthy G, Berer K, Lassmann H, Bosl MR, Dunn R, et al. Spontaneous relapsing-remitting eae in the sjl\/j mouse: Mog-reactive transgenic t cells recruit endogenous mog-specific b cells. J Exp Med. 2009;206:1303\u201316.","journal-title":"J Exp Med"},{"key":"1592_CR35","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/nbt1126","volume":"23","author":"HR Hoogenboom","year":"2005","unstructured":"Hoogenboom HR. Selecting and screening recombinant antibody libraries. Nat Biotechnol. 2005;23:1105\u201316.","journal-title":"Nat Biotechnol"},{"key":"1592_CR36","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.697876","volume":"11","author":"KDR Roth","year":"2021","unstructured":"Roth KDR, Wenzel EV, Ruschig M, Steinke S, Langreder N, Heine PA, et al. Developing recombinant antibodies by phage display against infectious diseases and toxins for diagnostics and therapy. Front Cell Infect Microbiol. 2021;11:697876.","journal-title":"Front Cell Infect Microbiol"},{"key":"1592_CR37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00401-023-02603-y","volume":"146","author":"MC Pham","year":"2023","unstructured":"Pham MC, Masi G, Patzina R, Obaid AH, Oxendine SR, Oh S, et al. Individual myasthenia gravis autoantibody clones can efficiently mediate multiple mechanisms of pathology. Acta Neuropathol. 2023;146:319\u201336.","journal-title":"Acta Neuropathol"},{"key":"1592_CR38","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jim.2007.09.017","volume":"329","author":"T Tiller","year":"2008","unstructured":"Tiller T, Meffre E, Yurasov S, Tsuiji M, Nussenzweig MC, Wardemann H. Efficient generation of monoclonal antibodies from single human b cells by single cell rt-pcr and expression vector cloning. J Immunol Methods. 2008;329:112\u201324.","journal-title":"J Immunol Methods"},{"key":"1592_CR39","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.ijbiomac.2019.06.006","volume":"135","author":"R Kumar","year":"2019","unstructured":"Kumar R, Parray HA, Shrivastava T, Sinha S, Luthra K. Phage display antibody libraries: a robust approach for generation of recombinant human monoclonal antibodies. Int J Biol Macromol. 2019;135:907\u201318.","journal-title":"Int J Biol Macromol"},{"key":"1592_CR40","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/sj.jid.5701132","volume":"128","author":"K Ishii","year":"2008","unstructured":"Ishii K, Lin C, Siegel DL, Stanley JR. Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of Pemphigus foliaceus autoantibodies. J Invest Dermatol. 2008;128:939\u201348.","journal-title":"J Invest Dermatol"},{"key":"1592_CR41","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/jid.2011.449","volume":"132","author":"MA Saleh","year":"2012","unstructured":"Saleh MA, Ishii K, Yamagami J, Shirakata Y, Hashimoto K, Amagai M. Pathogenic anti-desmoglein 3 mabs cloned from a paraneoplastic Pemphigus patient by phage display. J Invest Dermatol. 2012;132:1141\u20138.","journal-title":"J Invest Dermatol"},{"key":"1592_CR42","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0165-5728(99)00259-3","volume":"104","author":"D Papanastasiou","year":"2000","unstructured":"Papanastasiou D, Poulas K, Kokla A, Tzartos SJ. Prevention of passively transferred experimental autoimmune myasthenia gravis by fab fragments of monoclonal antibodies directed against the main immunogenic region of the acetylcholine receptor. J Neuroimmunol. 2000;104:124\u201332.","journal-title":"J Neuroimmunol"},{"key":"1592_CR43","doi-asserted-by":"publisher","first-page":"e2020635118","DOI":"10.1073\/pnas.2020635118","volume":"118","author":"DLE Vergoossen","year":"2021","unstructured":"Vergoossen DLE, Plomp JJ, Gstottner C, Fillie-Grijpma YE, Augustinus R, Verpalen R, et al. Functional monovalency amplifies the pathogenicity of anti-musk igg4 in myasthenia gravis. Proc Natl Acad Sci U S A. 2021;118:e2020635118.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1592_CR44","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/978-1-0716-4591-8_19","volume":"2937","author":"D Bedinger","year":"2025","unstructured":"Bedinger D, Parisot J, Ditto NT. Competitive epitope binning using ht-spr. Methods Mol Biol. 2025;2937:325\u201360.","journal-title":"Methods Mol Biol"},{"key":"1592_CR45","doi-asserted-by":"publisher","first-page":"12161","DOI":"10.1128\/JVI.75.24.12161-12168.2001","volume":"75","author":"M Hezareh","year":"2001","unstructured":"Hezareh M, Hessell AJ, Jensen RC, van de Winkel JG, Parren PW. Effector function activities of a panel of mutants of a broadly neutralizing antibody against Human Immunodeficiency Virus Type 1. J Virol. 2001;75:12161\u20138.","journal-title":"J Virol"},{"key":"1592_CR46","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0260954","volume":"16","author":"I Wilkinson","year":"2021","unstructured":"Wilkinson I, Anderson S, Fry J, Julien LA, Neville D, Qureshi O, et al. Fc-engineered antibodies with immune effector functions completely abolished. PLoS ONE. 2021;16:e0260954.","journal-title":"PLoS ONE"},{"key":"1592_CR47","doi-asserted-by":"publisher","first-page":"3900","DOI":"10.1074\/jbc.M116.767749","volume":"292","author":"M Lo","year":"2017","unstructured":"Lo M, Kim HS, Tong RK, Bainbridge TW, Vernes JM, Zhang Y, et al. Effector-attenuating substitutions that maintain antibody stability and reduce toxicity in mice. J Biol Chem. 2017;292:3900\u20138.","journal-title":"J Biol Chem"},{"key":"1592_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.biotechadv.2023.108201","volume":"67","author":"M Garcia-Alija","year":"2023","unstructured":"Garcia-Alija M, van Moer B, Sastre DE, Azzam T, Du JJ, Trastoy B, et al. Modulating antibody effector functions by Fc glycoengineering. Biotechnol Adv. 2023;67:108201.","journal-title":"Biotechnol Adv"},{"key":"1592_CR49","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1111\/j.1749-6632.1976.tb47693.x","volume":"274","author":"VA Lennon","year":"1976","unstructured":"Lennon VA, Lindstrom JM, Seybold ME. Experimental autoimmune myasthenia gravis: cellular and humoral immune responses. Ann N Y Acad Sci. 1976;274:283\u201399.","journal-title":"Ann N Y Acad Sci"},{"key":"1592_CR50","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1073\/pnas.80.13.4089","volume":"80","author":"CM Gomez","year":"1983","unstructured":"Gomez CM, Richman DP. Anti-acetylcholine receptor antibodies directed against the alpha-bungarotoxin binding site induce a unique form of experimental myasthenia. Proc Natl Acad Sci U S A. 1983;80:4089\u201393.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1592_CR51","doi-asserted-by":"publisher","first-page":"234","DOI":"10.4049\/jimmunol.135.1.234","volume":"135","author":"CM Gomez","year":"1985","unstructured":"Gomez CM, Richman DP. Monoclonal anti-acetylcholine receptor antibodies with differing capacities to induce experimental autoimmune myasthenia gravis. J Immunol. 1985;135:234\u201341.","journal-title":"J Immunol"},{"key":"1592_CR52","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1212\/WNL.36.5.622","volume":"36","author":"MC Souroujon","year":"1986","unstructured":"Souroujon MC, Pachner AR, Fuchs S. The treatment of passively transferred experimental myasthenia with anti-idiotypic antibodies. Neurology. 1986;36:622\u20135.","journal-title":"Neurology"},{"key":"1592_CR53","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/(SICI)1521-4141(199802)28:02<616::AID-IMMU616>3.0.CO;2-I","volume":"28","author":"D Barchan","year":"1998","unstructured":"Barchan D, Asher O, Tzartos SJ, Fuchs S, Souroujon MC. Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor. Eur J Immunol. 1998;28:616\u201324.","journal-title":"Eur J Immunol"},{"key":"1592_CR54","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1046\/j.1365-2249.2000.01202.x","volume":"120","author":"K Poulas","year":"2000","unstructured":"Poulas K, Tsouloufis T, Tzartos SJ. Treatment of passively transferred experimental autoimmune Myasthenia Gravis using papain. Clin Exp Immunol. 2000;120:363\u20138.","journal-title":"Clin Exp Immunol"},{"key":"1592_CR55","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/S0014-5793(03)00745-2","volume":"548","author":"B Hwang","year":"2003","unstructured":"Hwang B, Han K, Lee SW. Prevention of passively transferred experimental autoimmune Myasthenia Gravis by an in vitro selected RNA aptamer. FEBS Lett. 2003;548:85\u20139.","journal-title":"FEBS Lett"},{"key":"1592_CR56","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s00401-022-02493-6","volume":"144","author":"N Rose","year":"2022","unstructured":"Rose N, Holdermann S, Callegari I, Kim H, Fruh I, Kappos L, et al. Receptor clustering and pathogenic complement activation in Myasthenia Gravis depend on synergy between antibodies with multiple subunit specificities. Acta Neuropathol. 2022;144:1005\u201325.","journal-title":"Acta Neuropathol"},{"key":"1592_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-15187-2","volume":"15","author":"B Arets","year":"2025","unstructured":"Arets B, Mane-Damas M, Schottler AK, Sikorski PM, Kusner LL, Kaminski HJ, et al. Refinement of the rat acetylcholine receptor-specific passive transfer Myasthenia Gravis model using subcutaneous injections: An update to the guidelines. Sci Rep. 2025;15:33062.","journal-title":"Sci Rep"},{"key":"1592_CR58","first-page":"51303","volume":"85","author":"A Aartsma-Rus","year":"2014","unstructured":"Aartsma-Rus A, van Putten M. Assessing functional performance in the mdx mouse model. J Vis Exp. 2014;85:51303.","journal-title":"J Vis Exp"},{"key":"1592_CR59","doi-asserted-by":"publisher","DOI":"10.21769\/BioProtoc.5076","volume":"14","author":"YT Hsieh","year":"2024","unstructured":"Hsieh YT, Chen SL. Visualization and analysis of neuromuscular junctions using immunofluorescence. Bio Protoc. 2024;14:e5076.","journal-title":"Bio Protoc"},{"key":"1592_CR60","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.160240","author":"RA Jones","year":"2016","unstructured":"Jones RA, Reich CD, Dissanayake KN, Kristmundsdottir F, Findlater GS, Ribchester RR, et al. Nmj-morph reveals principal components of synaptic morphology influencing structure-function relationships at the neuromuscular junction. Open Biol. 2016. https:\/\/doi.org\/10.1098\/rsob.160240.","journal-title":"Open Biol"},{"key":"1592_CR61","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40259-020-00443-w","volume":"34","author":"S Alabbad","year":"2020","unstructured":"Alabbad S, AlGaeed M, Sikorski P, Kaminski HJ. Monoclonal antibody-based therapies for Myasthenia Gravis. BioDrugs. 2020;34:557\u201366.","journal-title":"BioDrugs"},{"key":"1592_CR62","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41586-021-03672-3","volume":"595","author":"J Oury","year":"2021","unstructured":"Oury J, Zhang W, Leloup N, Koide A, Corrado AD, Ketavarapu G, et al. Mechanism of disease and therapeutic rescue of DOK7 congenital Myasthenia. Nature. 2021;595:404\u20138.","journal-title":"Nature"},{"key":"1592_CR63","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1073\/pnas.85.9.2899","volume":"85","author":"SJ Tzartos","year":"1988","unstructured":"Tzartos SJ, Kokla A, Walgrave SL, Conti-Tronconi BM. Localization of the main immunogenic region of human muscle acetylcholine receptor to residues 67-76 of the alpha subunit. Proc Natl Acad Sci U S A. 1988;85:2899\u2013903.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1592_CR64","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","volume":"505","author":"AG Engel","year":"1987","unstructured":"Engel AG, Arahata K. The membrane attack complex of complement at the endplate in Myasthenia Gravis. Ann N Y Acad Sci. 1987;505:326\u201332.","journal-title":"Ann N Y Acad Sci"},{"key":"1592_CR65","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1097\/00005072-197803000-00008","volume":"37","author":"K Sahashi","year":"1978","unstructured":"Sahashi K, Engel AG, Linstrom JM, Lambert EH, Lennon VA. Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune Myasthenia Gravis. J Neuropathol Exp Neurol. 1978;37:212\u201323.","journal-title":"J Neuropathol Exp Neurol"},{"key":"1592_CR66","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","volume":"146","author":"BP Morgan","year":"2006","unstructured":"Morgan BP, Chamberlain-Banoub J, Neal JW, Song W, Mizuno M, Harris CL. The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice. Clin Exp Immunol. 2006;146:294\u2013302.","journal-title":"Clin Exp Immunol"},{"key":"1592_CR67","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1126\/science.850793","volume":"196","author":"I Kao","year":"1977","unstructured":"Kao I, Drachman DB. Myasthenic immunoglobulin accelerates acetylcholine receptor degradation. Science. 1977;196:527\u20139.","journal-title":"Science"},{"key":"1592_CR68","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1002\/(SICI)1097-4598(200004)23:4<453::AID-MUS3>3.0.CO;2-O","volume":"23","author":"JM Lindstrom","year":"2000","unstructured":"Lindstrom JM. Acetylcholine receptors and myasthenia. Muscle Nerve. 2000;23:453\u201377.","journal-title":"Muscle Nerve"},{"key":"1592_CR69","doi-asserted-by":"publisher","first-page":"20783","DOI":"10.1073\/pnas.1313944110","volume":"110","author":"MG Huijbers","year":"2013","unstructured":"Huijbers MG, Zhang W, Klooster R, Niks EH, Friese MB, Straasheijm KR, et al. MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and LRP4. Proc Natl Acad Sci U S A. 2013;110:20783\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1592_CR70","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/nyas.13561","volume":"1413","author":"MG Huijbers","year":"2018","unstructured":"Huijbers MG, Plomp JJ, van der Maarel SM, Verschuuren JJ. IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders. Ann N Y Acad Sci. 2018;1413:92\u2013103.","journal-title":"Ann N Y Acad Sci"},{"key":"1592_CR71","doi-asserted-by":"publisher","DOI":"10.1172\/JCI173308","author":"M Halliez","year":"2025","unstructured":"Halliez M, Cottin S, You A, Buon C, Grondin A, Lippens LS, et al. Musk cysteine-rich domain antibodies are pathogenic in a mouse model of autoimmune myasthenia gravis. J Clin Invest. 2025. https:\/\/doi.org\/10.1172\/JCI173308.","journal-title":"J Clin Invest"},{"key":"1592_CR72","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ab.2008.03.035","volume":"377","author":"Y Abdiche","year":"2008","unstructured":"Abdiche Y, Malashock D, Pinkerton A, Pons J. Determining kinetics and affinities of protein interactions using a parallel real-time label-free biosensor, the octet. Anal Biochem. 2008;377:209\u201317.","journal-title":"Anal Biochem"},{"key":"1592_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.xpro.2021.100836","volume":"2","author":"T Noy-Porat","year":"2021","unstructured":"Noy-Porat T, Alcalay R, Mechaly A, Peretz E, Makdasi E, Rosenfeld R, et al. Characterization of antibody-antigen interactions using biolayer interferometry. STAR Protoc. 2021;2:100836.","journal-title":"STAR Protoc"},{"key":"1592_CR74","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-7841-0_1","volume":"1785","author":"J Nilvebrant","year":"2018","unstructured":"Nilvebrant J, Rockberg J. An introduction to epitope mapping. Methods Mol Biol. 2018;1785:1\u201310.","journal-title":"Methods Mol Biol"},{"key":"1592_CR75","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1080\/07388551.2020.1869684","volume":"41","author":"H Kaur","year":"2021","unstructured":"Kaur H. Characterization of glycosylation in monoclonal antibodies and its importance in therapeutic antibody development. Crit Rev Biotechnol. 2021;41:300\u201315.","journal-title":"Crit Rev Biotechnol"},{"key":"1592_CR76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00520","volume":"5","author":"G Vidarsson","year":"2014","unstructured":"Vidarsson G, Dekkers G, Rispens T. IgG subclasses and allotypes: from structure to effector functions. Front Immunol. 2014;5:520.","journal-title":"Front Immunol"},{"key":"1592_CR77","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1084\/jem.144.3.739","volume":"144","author":"JM Lindstrom","year":"1976","unstructured":"Lindstrom JM, Engel AG, Seybold ME, Lennon VA, Lambert EH. Pathological mechanisms in experimental autoimmune myasthenia gravis. II. Passive transfer of experimental autoimmune myasthenia gravis in rats with anti-acetylcholine recepotr antibodies. J Exp Med. 1976;144:739\u201353.","journal-title":"J Exp Med"},{"key":"1592_CR78","doi-asserted-by":"publisher","first-page":"2947","DOI":"10.1093\/hmg\/ddh320","volume":"13","author":"J Cossins","year":"2004","unstructured":"Cossins J, Webster R, Maxwell S, Burke G, Vincent A, Beeson D. A mouse model of achr deficiency syndrome with a phenotype reflecting the human condition. Hum Mol Genet. 2004;13:2947\u201357.","journal-title":"Hum Mol Genet"},{"key":"1592_CR79","doi-asserted-by":"publisher","first-page":"13892","DOI":"10.1523\/JNEUROSCI.1733-14.2014","volume":"34","author":"A Barik","year":"2014","unstructured":"Barik A, Lu Y, Sathyamurthy A, Bowman A, Shen C, Li L, et al. Lrp4 is critical for neuromuscular junction maintenance. J Neurosci. 2014;34:13892\u2013905.","journal-title":"J Neurosci"},{"key":"1592_CR80","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.neuron.2012.04.033","volume":"75","author":"H Wu","year":"2012","unstructured":"Wu H, Lu Y, Shen C, Patel N, Gan L, Xiong WC, et al. Distinct roles of muscle and motoneuron lrp4 in neuromuscular junction formation. Neuron. 2012;75:94\u2013107.","journal-title":"Neuron"},{"key":"1592_CR81","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s40259-024-00701-1","volume":"39","author":"L Gerischer","year":"2025","unstructured":"Gerischer L, Doksani P, Hoffmann S, Meisel A. New and emerging biological therapies for myasthenia gravis: a focussed review for clinical decision-making. BioDrugs. 2025;39:185\u2013213.","journal-title":"BioDrugs"},{"key":"1592_CR82","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr.","year":"2017","unstructured":"Howard JF Jr., Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (regain): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol. 2017;16:976\u201386.","journal-title":"Lancet Neurol"},{"key":"1592_CR83","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","volume":"20","author":"JF Howard Jr.","year":"2021","unstructured":"Howard JF Jr., Bril V, Vu T, Karam C, Peric S, Margania T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (adapt): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021;20:526\u201336.","journal-title":"Lancet Neurol"},{"key":"1592_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12060817","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Jiang S. Roles of FcRn in antigen-presenting cells during autoimmunity and a clinical evaluation of Efgartigimod as an FcRn blocker. Pathogens. 2023. https:\/\/doi.org\/10.3390\/pathogens12060817.","journal-title":"Pathogens"}],"container-title":["Cell &amp; Bioscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13578-026-01592-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13578-026-01592-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13578-026-01592-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T01:23:22Z","timestamp":1785461002000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13578-026-01592-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":84,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1592"],"URL":"https:\/\/doi.org\/10.1186\/s13578-026-01592-1","relation":{},"ISSN":["2045-3701"],"issn-type":[{"value":"2045-3701","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"25 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"83"}}